EA004802B9 - МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ - Google Patents

МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ

Info

Publication number
EA004802B9
EA004802B9 EA200100943A EA200100943A EA004802B9 EA 004802 B9 EA004802 B9 EA 004802B9 EA 200100943 A EA200100943 A EA 200100943A EA 200100943 A EA200100943 A EA 200100943A EA 004802 B9 EA004802 B9 EA 004802B9
Authority
EA
Eurasian Patent Office
Prior art keywords
updated
filled
created automatically
empty document
empty
Prior art date
Application number
EA200100943A
Other languages
English (en)
Other versions
EA004802B1 (ru
EA200100943A1 (ru
Inventor
Биргер Сёренсен
Original Assignee
Бионор Иммуно Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионор Иммуно Ас filed Critical Бионор Иммуно Ас
Publication of EA200100943A1 publication Critical patent/EA200100943A1/ru
Publication of EA004802B1 publication Critical patent/EA004802B1/ru
Publication of EA004802B9 publication Critical patent/EA004802B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

Настоящее изобретение раскрывает новые модифицированные пептиды, способные индуцировать специфичный для ВИЧ-1 иммунный ответ без антагонизма в отношении активности цитотоксических T-клеток с целью получения эффективной профилактической и лечебной вакцины против ВИЧ. Пептиды основаны на консервативных участках белков gag ВИЧ p24. Разработаны антигены в свободной форме или присоединённые к носителю, включающие по крайней мере один из упомянутых пептидов, вакцинные композиции, включающие по крайней мере один из антигенов, наборы для иммуноанализа и способ определения антител, индуцированных ВИЧ или ВИЧ-специфичными пептидами, с использованием таких антигенов.
EA200100943A 1999-03-04 2000-03-02 МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ EA004802B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO19991078A NO311807B1 (no) 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
PCT/NO2000/000075 WO2000052040A1 (en) 1999-03-04 2000-03-02 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv

Publications (3)

Publication Number Publication Date
EA200100943A1 EA200100943A1 (ru) 2002-02-28
EA004802B1 EA004802B1 (ru) 2004-08-26
EA004802B9 true EA004802B9 (ru) 2015-03-31

Family

ID=19903050

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100943A EA004802B9 (ru) 1999-03-04 2000-03-02 МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ

Country Status (23)

Country Link
US (4) US6706859B1 (ru)
EP (1) EP1159298B1 (ru)
JP (5) JP2002541069A (ru)
CN (4) CN101328208A (ru)
AT (1) ATE397014T1 (ru)
AU (1) AU771827B2 (ru)
BR (1) BR0008741A (ru)
CA (1) CA2363947C (ru)
CY (1) CY1108299T1 (ru)
CZ (1) CZ300505B6 (ru)
DE (1) DE60039036D1 (ru)
DK (1) DK1159298T3 (ru)
EA (1) EA004802B9 (ru)
ES (1) ES2307496T4 (ru)
HK (1) HK1044778B (ru)
HU (1) HU229282B1 (ru)
ID (1) ID30497A (ru)
NO (1) NO311807B1 (ru)
NZ (4) NZ525752A (ru)
PT (1) PT1159298E (ru)
SK (1) SK287382B6 (ru)
WO (1) WO2000052040A1 (ru)
ZA (1) ZA200107072B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150961A0 (en) 2000-02-04 2003-02-12 Univ Duke Human immunodeficiency virus vaccine
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
UA97800C2 (ru) 2006-03-10 2012-03-26 Пептселл Лімітед Пептидные последовательности и композиции
CN102123724B (zh) 2008-06-19 2018-05-01 变异生技公司 治疗流行性感冒的组合物和方法
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
AU2011335551B2 (en) * 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
WO2013182660A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
WO2013182661A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
WO2015022401A1 (en) * 2013-08-14 2015-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunoadjuvant compositions and uses thereof
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015086738A2 (en) * 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
WO2015110659A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
CA2936335A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Dosage regimen for hiv vaccine
US10143737B2 (en) 2014-01-27 2018-12-04 Bionor Pharma Asa Method for the vaccination against HIV
EP4219526A3 (en) 2014-04-03 2023-08-30 Amgen, Inc. Method for preparing amg 416
EP3166633A1 (en) 2014-07-11 2017-05-17 Bionor Immuno AS Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CA2984991A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028871A1 (en) * 1993-06-07 1994-12-22 Endocon, Inc. Implant stimulated cellular immunity
WO1995011255A1 (fr) * 1993-10-19 1995-04-27 Ajinomoto Co., Inc. Peptide pouvant induire une reponse immune contre vih et agent contenant ce peptide pour la prevention ou le traitement du sida
WO1996027013A1 (fr) * 1995-02-27 1996-09-06 Institut National De La Sante Et De La Recherche Medicale-Inserm Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
WO1998040744A1 (de) * 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230222A1 (en) 1986-01-06 1987-07-29 F. Hoffmann-La Roche Ag Expression of HTLV-III gag-Gene
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
NZ226026A (en) 1987-09-04 1991-03-26 Wellcome Found Immunoassay for an antibody using recombinant antigens expressed in two different genera
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
EP0356007A3 (en) * 1988-07-22 1991-07-03 Medical Research Council Antigenic determinants
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
FR2703252B1 (fr) * 1993-03-31 1996-09-06 Fernand Narbey Torossian Complexe immunomodulateur anti SIDA.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028871A1 (en) * 1993-06-07 1994-12-22 Endocon, Inc. Implant stimulated cellular immunity
WO1995011255A1 (fr) * 1993-10-19 1995-04-27 Ajinomoto Co., Inc. Peptide pouvant induire une reponse immune contre vih et agent contenant ce peptide pour la prevention ou le traitement du sida
WO1996027013A1 (fr) * 1995-02-27 1996-09-06 Institut National De La Sante Et De La Recherche Medicale-Inserm Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
WO1998040744A1 (de) * 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Human Retroviruses and Aids, Bette Korber: "A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences", 1997, see page II-A-1-15 *
J. Virol, Volume 73, No 1, January 1999, Lole KS et al., "Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination", page 152 - page 160, see locus AAD12087 a.a. 164-182 *
Nature, Volume 354, December 1991, Rodney E. Philips et al., "Human immunodeficiency virus genetic variation that can escape cytoxic T cell recognition", page 453 - page 459, table 1, page 24, res 255-271 *

Also Published As

Publication number Publication date
CZ20013195A3 (cs) 2002-02-13
NZ525751A (en) 2004-10-29
CZ300505B6 (cs) 2009-06-03
ZA200107072B (en) 2002-11-27
SK287382B6 (sk) 2010-08-09
ID30497A (id) 2001-12-13
JP5695012B2 (ja) 2015-04-01
US6706859B1 (en) 2004-03-16
CN101328209A (zh) 2008-12-24
EA004802B1 (ru) 2004-08-26
ES2307496T4 (es) 2015-03-06
NZ525752A (en) 2004-10-29
EA200100943A1 (ru) 2002-02-28
DK1159298T3 (da) 2008-08-25
AU771827B2 (en) 2004-04-01
US20040259797A1 (en) 2004-12-23
CY1108299T1 (el) 2014-02-12
CA2363947C (en) 2008-05-20
CN100387617C (zh) 2008-05-14
CA2363947A1 (en) 2000-09-08
CN1346367A (zh) 2002-04-24
HU229282B1 (en) 2013-10-28
US7311915B2 (en) 2007-12-25
ES2307496T3 (es) 2008-12-01
EP1159298A1 (en) 2001-12-05
SK12402001A3 (sk) 2002-02-05
EP1159298B1 (en) 2008-05-28
NO311807B1 (no) 2002-01-28
JP5313998B2 (ja) 2013-10-09
JP2013032384A (ja) 2013-02-14
AU3335800A (en) 2000-09-21
HK1044778A1 (en) 2002-11-01
US7709003B2 (en) 2010-05-04
US20080107670A1 (en) 2008-05-08
JP2013032386A (ja) 2013-02-14
JP5695010B2 (ja) 2015-04-01
DE60039036D1 (de) 2008-07-10
JP5814331B2 (ja) 2015-11-17
NZ525753A (en) 2004-10-29
NO991078D0 (no) 1999-03-04
HK1044778B (zh) 2009-04-24
US20080107669A1 (en) 2008-05-08
NO991078L (no) 2000-09-05
NZ514619A (en) 2003-10-31
WO2000052040A1 (en) 2000-09-08
JP2011074081A (ja) 2011-04-14
ATE397014T1 (de) 2008-06-15
PT1159298E (pt) 2008-09-04
JP2014043468A (ja) 2014-03-13
US7709004B2 (en) 2010-05-04
HUP0200265A2 (en) 2002-06-29
JP2002541069A (ja) 2002-12-03
CN101328208A (zh) 2008-12-24
BR0008741A (pt) 2002-01-08
CN101328210A (zh) 2008-12-24

Similar Documents

Publication Publication Date Title
EA004802B9 (ru) МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ
AU7442800A (en) Determining trends using text mining
GB0005268D0 (en) Document creation and delivery
IL147803A0 (en) 28-epirapalogs
EP1153845A4 (en) DISTRIBUTION CONTAINER
AU2001268320A8 (en) Personalized content management
MXPA02004923A (es) Recipiente y cierre para el mismo.
EP1220788A4 (en) CONTAINER WITH MESSAGE
GB0030968D0 (en) Managing mutiple radiotelephones
TW399609U (en) Container assembly and container unit
ZA996847B (en) Container with retaining member.
MXPA01011309A (es) Composiciones que contienen bencimidazolonas y progestagenos.
CA96355S (en) Dispensing container
GC0000057A (en) Pre- filled container.
GB0021915D0 (en) Creating and managing E-receipts
AU7264700A (en) Two-chamber container and method for gassing the same
HU0002268D0 (en) Arrangement for compliting and transmitting text messages
GB2286608B (en) W.C. Cistern with tiltably-mounted container
GB9817049D0 (en) Discrete automatically controlled high level non-wheeled conveyance
FR2801871B1 (fr) Recipient avec son couvercle
CA98147S (en) Sliding bracket
GB2350834B (en) Transportation container
TW465385U (en) Garbage can with shredder function
GB9917229D0 (en) Creation and transmission of text messages
GB9925736D0 (en) Email format

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU